Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
Date:9/14/2007

7 stock offering and the receipt of $10 million from AstraZeneca upon the signing of the companies' research collaboration and license agreement.

Palatin Technologies' management will discuss the fourth quarter and year end financial results for the fiscal year ended June 30, 2007 and provide an update on corporate developments during a conference call and webcast on September 18, 2007 at 10:00 a.m. ET.

Conference Call and Webcast Access Information

-- Q4-Fiscal Year 2007 Conference Call - Live 9/18/2007 at 10:00 a.m. ET

Domestic Dial-In Number 1-866-454-4203

International Dial-In Number 1-913-312-6693

-- Q4-Fiscal Year 2007 Conference Call - Replay 9/18-9/25/2007

Domestic Dial-In Number 1-888-203-1112

International Dial-In Number 1-719-457-0820

Enter Pass Code I.D. # 4280242

-- Webcast Live and Replay Access http://www.palatin.com

The webcast and replay can be accessed by logging on to the investors

section of Palatin Technologies' website at http://www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. The Company currently has collaborations with AstraZeneca and the Mallinckrodt division of Covidien. For additional information regarding Palatin, please visit Palatin Technologies' websit
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Age of Unreason," an important book in which author ... business-affecting change. Though an economist, Handy could not have ... our current recession, yet he offers a prescient perspective ... a shift from manufacturing- to a knowledge-based economy. , ...
... challenging, but knowing how to conduct the proper interviews can ... getting the right person. If its a top executive position ... of the candidates background is critical, but having a method ... experiences increases the chances of hiring the right person. ...
... Catalyst International, a global provider of supply ... of platform-independent SCE applications. , ,"We're expanding and ... increasing demand for integrated fulfillment solutions from supplier ... said Jim Treleaven, President and CEO of Catalyst. ...
Cached Biology Technology:The Molecular Organization 2The Molecular Organization 3Improving the Hiring Process 2
(Date:7/11/2014)... release is available in German . ... a method that uses the refraction of X-rays through ... images produced with this method are often of much ... in the team of Prof. Franz Pfeiffer are particularly ... and therapy including X-ray phase-contrast imaging. One main ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... first comprehensive multi-model-based assessment of so-called Durban Platform scenarios, ... the Potsdam Institute for Climate Impact Research (PIK) and ... Durban Platform is the current negotiation track at the ... climate agreement by 2015 to come into effect in ...
... developing a comprehensive data system that can be used ... them with access to chemical toxicity information. ... the "automated profiling system" from existing bioassay data from ... help scientists who are seeking information on chemicals of ...
... continues to support the role of protein in building and ... embracing the important role of protein in the diet. ... out that protein quality really does matter. The latest ... at SupplySide West, the leading destination for the exploration, discovery, ...
Cached Biology News:Success of climate talks vital for 2°C target 2Success of climate talks vital for 2°C target 3Toxicity database under development at Rutgers-Camden 2Protein quality: It matters 2Protein quality: It matters 3
... immunowash microplate washer 100-240 V, is used ... U-, or V-bottom wells. The immunowash microplate ... needle positions to an accuracy of 0.1 ... overflow washing. It can store up to ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
... RM is specifically designed as a high ... new variable mass compensation allows high shaking ... better aeration and, therefore, faster growth and ... is ideal when high reproducibility is critical ...
...
Biology Products: